A Phase 1 study of ONO-4538 in combination with chemotherapy in patients with stage IIIB/IV or recurrent NSCLC
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Feb 2018
At a glance
- Drugs Nivolumab (Primary) ; Bevacizumab; Carboplatin; Cisplatin; Docetaxel; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Ono Pharmaceutical
- 12 Feb 2018 Planned End Date changed from 1 Mar 2017 to 1 Mar 2020.
- 18 Oct 2017 Results (n=24) assessing long term follow up of tolerability, safety and pharmacokinetics presented at the 18th World Conference on Lung Cancer.
- 20 Oct 2016 Results (n=24, as of March 2014) published in the Annals of Oncology